Epigenomics terminated its collaboration with China's BioChain for the licensing of the septin9 marker and exclusive Chinese distribution rights for Epi proColon.
Galaxy has licensed IP from Proteome Sciences for the development of a test for the diagnosis and timing of stroke onset to help inform treatment decisions.
Genfit's assay will be deployed through Covance's central laboratories to validate its use to better identify and characterize patients with the liver disease.
Precision Pathology will develop the CyPath Lung test for early-stage detection of lung cancer as an LDT for commercial sale by the first-quarter of 2019.